Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug ...

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals RXRX is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release. Analysts are ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Microsoft’s Copilot generative AI is popping up on the web, in mobile apps, in the Edge browser, and especially in Windows. But just what exactly is it? Here’s everything you need to know. I've been ...

Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages artificial intelligence (AI), automation, and experimental biology to accelerate the discovery and development of new ...

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.